DOSSIER · 13F-HR · Q2 2026

Palo Alto Investors LP

$724M in tracked AUM across 52 positions as of Q2 2026.

PA
CIK 0001306923 · last filed Jun 30, 2026
Total AUM
$724M
as of Q2 2026
Holdings
52
—
positions
Whale Score
69
69
tracked
Activity
—
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Palo Alto Investors LP (SEC 13F) – Q3 2025
1. Portfolio Overview

Palo Alto Investors LP manages a concentrated, high-conviction portfolio characterized by a significant reduction in size and a pivot towards specific healthcare sub-sectors. As of the report date September 30, 2025, the total portfolio value stands at approximately $341.95 million, representing a sharp decrease of 27.2% from the previous quarter's $470.00 million.

The portfolio is highly concentra...

2. Key Holdings

The portfolio exhibits a "barbell" structure where a handful of top positions account for a significant portion of the total assets. The top five holdings comprise a massive 52.53% of the total portfolio value.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
PTCT
PTC THERAPEUTICS INC
$75M919K10.4%
02
ACAD
ACADIA PHARMACEUTICALS INC
$72M2.9M10.0%
03
INSM
INSMED INC
$44M414K6.1%
04
MIRM
MIRUM PHARMACEUTICALS INC
$41M349K5.6%
05
ANAB
ANAPTYSBIO INC
$41M603K5.6%
06
BMRN
BIOMARIN PHARMACEUTICAL INC
$39M683K5.4%
07
DYN
DYNE THERAPEUTICS INC
$37M1.6M5.1%
08
UTHR
UNITED THERAPEUTICS CORP
$34M63K4.7%
09
IRON
DISC MEDICINE INC
$30M417K4.2%
10
BIIB
BIOGEN INC
$30M140K4.2%

Filing history

2026Q2Jun 30
$724M▲ 10.7%
52 positionsView →
2026Q1Mar 31
$654M▼ 9.0%
51 positionsView →
2025Q4Dec 31
$718M▲ 110.1%
49 positionsView →
2025Q3Sep 30
$342M▼ 27.2%
31 positionsView →
2025Q2Jun 30
$470M▲ 40.2%
45 positionsLocked
2025Q1Mar 31
$335M▼ 48.0%
31 positionsLocked
2024Q4Dec 31
$645M▼ 16.2%
43 positionsLocked
2024Q3Sep 30
$770M▼ 10.8%
45 positionsLocked
2024Q2Jun 30
$863M▼ 2.7%
39 positionsLocked
2024Q1Mar 31
$887M▼ 20.1%
38 positionsLocked
2023Q4Dec 31
$1.1B▲ 5.0%
34 positionsLocked
2023Q3Sep 30
$1.1B▼ 14.6%
29 positionsLocked
Showing 12 of 76